MedTrace Logo

The Influence of Raltegravir on Pravastatin Pharmacokinetics(GRAPPA)

NCT00665717 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2020-10-19

No results posted yet for this study

Summary

The purpose of this trial is to determine the effect of raltegravir on pravastatin pharmacokinetics and vice versa by intrasubject comparison.

Conditions

  • HIV Infections

Interventions

DRUG

Pravastatin

40 mg tablet; QD; 4 days

DRUG

Raltegravir

400mg tablet; BD 4 days

DRUG

Pravastatin and raltegravir

pravastatin 40mg tablet QD for 4 days; raltegravir 400mg tablet BD for 4 days

Sponsors & Collaborators

Principal Investigators

  • David M Burger, PharmD PhD · Radboud University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2008-09-30
Completion
2008-10-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00665717 on ClinicalTrials.gov